Company research
X4 Pharmaceuticals, Inc
CIK 1501697Updated Nov 17, 2026
Historical securities (2)
XFORW · OTC · warrant · closed Apr 16, 2024XFOWW · OTC · warrant · closed Nov 27, 2024XFOR price & chart
Loading TradingView…
NASDAQ:XFOR on TradingView ↗About the company
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare hematology diseases and significant unmet needs. Leveraging expertise in CXCR4, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain
In the news
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
10-Q filing
Other Events
Items 8.01, 9.01
4 filing
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 1.02, 2.03, 3.02, 7.01, 9.01
SCHEDULE 13G/A - filed by FMR LLC regarding X4 Pharmaceuticals, Inc
Show 5 more recent filings
4 filing
144 filing
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
SCHEDULE 13G/A - filed by Deep Track Capital, LP regarding X4 Pharmaceuticals, Inc
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 163,555,000Source | 178,165,000Source | 253,063,000Source | 105,168,000Source | 210,611,000Source | 270,281,000Source | 130,013,000Source | 112,182,000Source | 290,461,000Source | 146,447,000Source | 147,258,000Source | 155,586,000Source |
| Property, Plant and Equipment, NetUSD | 218,000Source | 820,000Source | 111,000Source | 254,000Source | 808,000Source | 146,000Source | 487,000Source | 742,000Source | 182,000Source | 776,000Source | 745,000Source | 1,104,000Source |
| GoodwillUSD | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 69,632,000Source | 97,412,000Source | 195,095,000Source | 39,220,000Source | 147,218,000Source | 216,908,000Source | 40,257,000Source | 60,493,000Source | 217,049,000Source | 55,699,000Source | 99,216,000Source | 121,718,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 891,000Source | 0Source | 2,047,000Source | 1,145,000Source | 0Source | 1,113,000Source | 509,000Source | — | 573,000Source | 1,070,000Source | — | — |
| Inventory, NetUSD | — | — | — | — | — | — | — | — | — | 2,817,000Source | — | — |
| Assets, CurrentUSD | 132,805,000Source | 142,972,000Source | 218,855,000Source | 72,942,000Source | 175,416,000Source | 241,982,000Source | 95,697,000Source | 87,333,000Source | 261,577,000Source | 112,175,000Source | 122,076,000Source | 128,677,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,925,000Source | 4,477,000Source | 3,337,000Source | 4,956,000Source | 4,977,000Source | 2,512,000Source | 4,483,000Source | 5,762,000Source | 3,527,000Source | 5,588,000Source | 7,298,000Source | 5,807,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,775,000Source | 4,471,000Source | 654,000Source | 2,646,000Source | 4,872,000Source | 1,035,000Source | 3,652,000Source | 5,264,000Source | 1,409,000Source | 4,065,000Source | 5,650,000Source | 7,229,000Source |
| Other Assets, NoncurrentUSD | 1,968,000Source | 2,363,000Source | 2,991,000Source | 2,350,000Source | 1,789,000Source | 704,000Source | 3,013,000Source | 1,492,000Source | 692,000Source | 2,080,000Source | 1,436,000Source | 1,225,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 101,936,000Source | 118,544,000Source | 97,609,000Source | 101,197,000Source | 116,160,000Source | 101,831,000Source | 107,069,000Source | 111,146,000Source | 104,171,000Source | 124,298,000Source | 96,159,000Source | 81,535,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 25,000Source | 168,000Source | 96,000Source | 8,000Source | 168,000Source | 94,000Source | 6,000Source | 168,000Source | 91,000Source | 171,000Source | 167,000Source | 122,000Source |
| Retained Earnings (Accumulated Deficit)USD | -570,629,000Source | -475,534,000Source | -630,952,000Source | -540,814,000Source | -438,838,000Source | -614,795,000Source | -515,073,000Source | -529,671,000Source | -594,554,000Source | -515,355,000Source | -477,905,000Source | -376,738,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -118,000Source | -114,000Source | -123,000Source | -138,000Source | -159,000Source | -122,000Source | -128,000Source | -155,000Source | -109,000Source | -122,000Source | -119,000Source | -119,000Source |
| Stockholders' Equity Attributable to ParentUSD | 61,619,000Source | 59,621,000Source | 155,454,000Source | 3,971,000Source | 94,451,000Source | 168,450,000Source | 22,944,000Source | 1,036,000Source | 186,290,000Source | 22,149,000Source | 51,099,000Source | 74,051,000Source |
| Additional Paid in Capital, Common StockUSD | 632,341,000Source | 535,101,000Source | 786,433,000Source | 544,915,000Source | 533,280,000Source | 783,273,000Source | 538,139,000Source | 530,694,000Source | 780,862,000Source | 537,455,000Source | 528,956,000Source | 450,786,000Source |
| Liabilities and EquityUSD | 163,555,000Source | 178,165,000Source | 253,063,000Source | 105,168,000Source | 210,611,000Source | 270,281,000Source | 130,013,000Source | 112,182,000Source | 290,461,000Source | 146,447,000Source | 147,258,000Source | 155,586,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 23,506,000Source | 29,258,000Source | 19,366,000Source | 22,896,000Source | 28,902,000Source | 23,771,000Source | 25,884,000Source | 23,541,000Source | 25,757,000Source | 32,877,000Source | 22,862,000Source | 22,324,000Source |
| Operating Lease, Liability, CurrentUSD | 1,200,000Source | 1,222,000Source | 465,000Source | 1,368,000Source | 1,172,000Source | 733,000Source | 1,303,000Source | 1,133,000Source | 994,000Source | 1,251,000Source | 1,099,000Source | 1,198,000Source |
| Accounts Payable, CurrentUSD | 5,053,000Source | 8,577,000Source | 3,934,000Source | 7,709,000Source | 7,986,000Source | 5,073,000Source | 11,115,000Source | 8,935,000Source | 5,696,000Source | 8,621,000Source | 8,947,000Source | 7,777,000Source |
| Operating Lease, Liability, NoncurrentUSD | 95,000Source | 1,757,000Source | — | 815,000Source | 2,026,000Source | — | 1,109,000Source | 2,318,000Source | 0Source | 1,410,000Source | 2,612,000Source | 3,603,000Source |
| Other Liabilities, NoncurrentUSD | 525,000Source | 1,218,000Source | 523,000Source | 535,000Source | 979,000Source | 526,000Source | 567,000Source | 1,025,000Source | 525,000Source | 831,000Source | 432,000Source | 173,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 16,661,000Source | 19,459,000Source | 14,125,000Source | 13,065,000Source | 19,744,000Source | 17,055,000Source | 12,611,000Source | 13,473,000Source | 18,603,000Source | 23,005,000Source | 12,816,000Source | 12,034,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 122,200,000Source | 135,000,000Source | 208,000,000Source | 63,000,000Source | 168,800,000Source | 233,700,000Source | 87,000,000Source | 80,900,000Source | 253,000,000Source | 102,100,000Source | 114,200,000Source | — |
| Long-term DebtUSD | 75,000,000Source | 75,000,000Source | 75,000,000Source | 75,000,000Source | 75,000,000Source | 75,000,000Source | 75,000,000Source | 55,000,000Source | 75,000,000Source | 75,000,000Source | 54,570,000Source | 32,304,000Source |
| Long-term Debt, Current MaturitiesUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 1,315,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | — | — | — | — | — | — | — | 54,570,000Source | 32,304,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | -37,450,000Source | -101,167,000Source | -93,867,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 223,000Source | 476,000Source | 1,277,000Source | 796,000Source | 419,000Source | 513,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,413,000Source | 519,000Source | 4,298,000Source | 8,204,000Source | 8,687,000Source | 5,199,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 541,000Source | -561,000Source | -497,000Source | 1,070,000Source | — | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 158,000Source | 272,000Source | 1,662,000Source | 2,817,000Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -624,000Source | 2,476,000Source | -2,979,000Source | -286,000Source | 1,234,000Source | 3,425,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -19,599,000Source | -12,368,000Source | -85,618,000Source | -130,901,000Source | -96,512,000Source | -77,102,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 19,252,000Source | -3,138,000Source | 8,154,000Source | 66,990,000Source | -14,883,000Source | -103,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 326,000Source | — | — |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 12,000Source |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 2,000Source | 0Source | 238,628,000Source | 20,294,000Source | 88,516,000Source | 117,230,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 2,064,000Source | 795,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -365,000Source | -15,434,000Source | 161,377,000Source | -43,773,000Source | -22,780,000Source | 39,920,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 70,435,000Source | 98,200,000Source | 195,769,000Source | 40,022,000Source | 217,487,000Source | 41,041,000Source | 217,852,000Source | 56,475,000Source | 100,248,000Source | 123,028,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 8,053,000Source | 7,766,000Source | 4,604,000Source | 3,006,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 338,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -20,000Source | 72,000Source | 213,000Source | -156,000Source | 99,000Source | -105,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 760,000Source | 1,820,000Source | 3,086,000Source | 748,000Source | 2,413,000Source | 519,000Source | 4,298,000Source | 8,204,000Source | 8,687,000Source | 5,199,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | 500,000Source | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 122,200,000Source | 135,000,000Source | 208,000,000Source | 63,000,000Source | 233,700,000Source | 87,000,000Source | 253,000,000Source | 102,100,000Source | 114,200,000Source | — |
| DepreciationUSD | — | — | — | — | — | — | 36,000Source | 289,000Source | 500,000Source | — | — | — |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | -676,000Source | -1,864,000Source | 528,000Source | 2,642,000Source | 80,000Source | 10,830,000Source | 12,778,000Source | 1,928,000Source | 7,074,000Source | 1,701,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | 0Source | 0Source | — | 0Source | — | — | 0Source | 105,000,000Source | 0Source | 509,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 11,586,000Source | 15,660,000Source | 8,501,000Source | 9,527,000Source | 6,966,000Source | 15,021,000Source | 43,516,000Source | 61,518,000Source | 35,505,000Source | 27,020,000Source |
| GoodwillUSD | — | — | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | -30,000Source | 15,000Source | 2,000Source | 37,000Source | 0Source | 34,000Source | 41,000Source | 310,000Source | 78,000Source | 28,000Source |
| InterestExpenseNonoperatingUSD | — | — | 2,257,000Source | 2,414,000Source | 2,164,000Source | 2,232,000Source | 2,134,000Source | 2,201,000Source | 8,876,000Source | 8,768,000Source | — | — |
| Investment Income, InterestUSD | — | — | 901,000Source | 1,871,000Source | 1,979,000Source | 665,000Source | 2,105,000Source | 1,025,000Source | 4,576,000Source | 5,769,000Source | 4,582,000Source | 219,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | 20,000Source | 45,000Source | -1,000Source | -10,000Source | -13,000Source | -6,000Source | 13,000Source | -3,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -29,815,000Source | -36,696,000Source | -16,157,000Source | -25,741,000Source | -20,241,000Source | 282,000Source | -79,199,000Source | -37,450,000Source | -101,167,000Source | -93,867,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | -37,450,000Source | -101,167,000Source | -96,413,000Source |
| Nonoperating Income (Expense)USD | — | — | -2,336,000Source | -2,181,000Source | 236,000Source | 528,000Source | 65,000Source | 9,759,000Source | 7,725,000Source | -739,000Source | 6,433,000Source | -6,270,000Source |
| Operating ExpensesUSD | — | — | — | — | — | — | — | — | — | — | 107,522,000Source | 87,569,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -304,000Source | 226,000Source | -107,000Source | -547,000Source | 14,000Source | 105,000Source | -753,000Source | 332,000Source | 554,000Source | -4,197,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 238,530,000Source | — | — | — |
| Amortization | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Gain (Loss) on Disposition of Assets | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Gain (Loss) on Disposition of Assets for Financial Service Operations | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,765,000Source | 560,000Source | 8,806,000Source | 1,973,000Source | 2,708,000Source | 28,807,000Source | 35,113,000Source | 2,557,000Source | — | 0Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income (Loss)USD | — | — | -27,509,000Source | -34,500,000Source | -16,391,000Source | -26,232,000Source | -20,306,000Source | -9,443,000Source | -86,883,000Source | -36,401,000Source | -107,522,000Source | -87,569,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -304,000Source | 226,000Source | -107,000Source | -547,000Source | 14,000Source | 105,000Source | -753,000Source | 332,000Source | 554,000Source | -4,197,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -29,845,000Source | -36,681,000Source | -16,155,000Source | -25,704,000Source | -20,241,000Source | 316,000Source | -79,158,000Source | -37,140,000Source | -101,089,000Source | -93,839,000Source |
| Income Tax Expense (Benefit)USD | — | — | -30,000Source | 15,000Source | 2,000Source | 37,000Source | 0Source | 34,000Source | 41,000Source | 310,000Source | 78,000Source | 28,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -29,815,000Source | -36,696,000Source | -16,157,000Source | -25,741,000Source | -20,241,000Source | 282,000Source | -79,199,000Source | -37,450,000Source | -101,167,000Source | -93,867,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.69Source | -5.48Source | -0.13Source | -3.47Source | -0.16Source | 0.04Source | -1.87Source | -0.19Source | -0.57Source | -1.52Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.69Source | -5.48Source | -0.13Source | -3.47Source | -0.16Source | 0.04Source | -1.87Source | -0.19Source | -0.57Source | -1.52Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 43,272,773Source | 6,695,509Source | 126,344,020Source | 7,412,990Source | 126,288,723Source | 6,840,035Source | 42,292,818Source | 201,062,211Source | 177,812,480Source | 63,526,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 43,272,773Source | 6,695,509Source | 126,344,020Source | 7,412,990Source | 126,288,723Source | 6,869,084Source | 42,292,818Source | 201,062,211Source | 177,812,480Source | 63,526,000Source |
| Interest Expense (non-operating)USD | — | — | 2,257,000Source | 2,414,000Source | 2,164,000Source | 2,232,000Source | 2,134,000Source | 2,201,000Source | 8,876,000Source | 8,768,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | 500,000Source | — | — |
| Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | 38,958,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 11,586,000Source | 15,660,000Source | 8,501,000Source | 9,527,000Source | 6,966,000Source | 15,021,000Source | 43,516,000Source | 61,518,000Source | 35,505,000Source | 27,020,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -79,409,000Source | -38,846,000Source | -102,126,000Source | -94,742,000Source |
| Interest ExpenseUSD | — | — | — | 2,414,000Source | — | — | — | — | — | — | 5,777,000Source | 3,993,000Source |
| Investment Income, InterestUSD | — | — | 901,000Source | 1,871,000Source | 1,979,000Source | 665,000Source | 2,105,000Source | 1,025,000Source | 4,576,000Source | 5,769,000Source | 4,582,000Source | 219,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | -37,450,000Source | -101,167,000Source | -96,413,000Source |
| Nonoperating Income (Expense)USD | — | — | -2,336,000Source | -2,181,000Source | 236,000Source | 528,000Source | 65,000Source | 9,759,000Source | 7,725,000Source | -739,000Source | 6,433,000Source | -6,270,000Source |
| Operating ExpensesUSD | — | — | — | — | — | — | — | — | — | — | 107,522,000Source | 87,569,000Source |
| Research and Development ExpenseUSD | — | — | 17,337,000Source | 19,173,000Source | 15,079,000Source | 18,352,000Source | 15,450,000Source | 18,513,000Source | 72,723,000Source | 81,643,000Source | 72,017,000Source | 61,058,000Source |
Offerings
Registration 333-295597
Filing attachments
ex991_x4presentation.htm · 8-K · 2026-10-29
Virtual Investor Day October 29, 2026 Nasdaq: XFOR Exhibit 99.1 2 This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question-and-answer sessions and any documents or materials distributed at or in connection with the presentation, contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation…
Read attachment ↗ex41formofdebenturemay2026.htm · S-3 · 2026-05-06
Exhibit 4.1 X4 PHARMACEUTICALS, INC. Debt Securities Indenture Dated as of, 202 [ ], as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) …
Read attachment ↗xforex41formofpre-fundedwa.htm · 8-K · 2025-10-27
EX-4.1 3 xforex41formofpre-fundedwa.htm EX-4.1 Document Exhibit 4.1 X4 PHARMACEUTICALS, INC. [FORM OF] PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [l] (subject to adjustment) Warrant No. PF-2025-[l] Original Issue Date: [l], 2025 X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [l] or its registered assigns (the “Holder”), is entit…
Read attachment ↗ex991_2025916release.htm · 8-K · 2025-09-17
EX-99.1 2 ex991_2025916release.htm EX-99.1 Document Exhibit 99.1 X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M John Volpone appointed Chief Operating Officer, in addition to his current role as President Dr. Adam Craig, Executive Chairman, to have oversight over clinical develop…
Read attachment ↗ex-41formofaugust2025prexf.htm · 8-K · 2025-08-12
EX-4.1 2 ex-41formofaugust2025prexf.htm EX-4.1 Document Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE S…
Read attachment ↗